SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Michael Axelrod was appointed as President and Chief Executive Officer and Board member effective July 29, 2026, following a comprehensive external search. The appointment includes detailed compensation arrangements including a base salary of $1,000,000 and equity awards of $4,750,000, along with severance and change-in-control protections.
View raw filing on EDGAR →The filing discloses the appointment of Charles Weiser as Chief Financial Officer effective July 1, 2026, along with a detailed employment agreement specifying base salary ($225,000), performance bonus (up to 75% of base), signing bonus ($25,000), and equity grants (150,000 options and 125,000 RSUs). While the disclosure includes compensatory arrangements, the principal disclosed action is the appointment of a named executive to a C-suite officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors assessing the registrant's financial leadership and governance.
View raw filing on EDGAR →Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. McDonnell brings extensive CFO experience from major life sciences companies including Biogen and IQVIA.
View raw filing on EDGAR →The 6-K discloses the appointment of two new directors effective July 1, 2026: Ruobai Sima (the Company's existing CFO since May 2022) and Han Jiang (an external candidate with art and design expertise). While the report also discloses two director departures (Jun Zhang and Andrew Y. Yan, both citing personal reasons), the principal disclosed action is the appointment of new board members. The appointment of the CFO to the board and the addition of a new independent director are material governance changes affecting board composition and oversight.
View raw filing on EDGAR →Muhammad Asif Seemab was appointed President and Interim Chief Executive Officer effective July 6, 2026, following the concurrent resignation of Muhammad Umair from the CEO role.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the prose centers on Slutsky's promotion to a senior operational role with expanded responsibilities overseeing legal, compliance, technology, trading, administration, and human resources. The detailed biographical and compensation information provided for Slutsky (age, education, tenure, salary eligibility, post-employment obligations) emphasizes the appointment as the principal disclosed action, making this an exec_appointment event.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the filing's primary focus and detailed disclosure center on Slutsky's appointment to the COO role, including his background, responsibilities, and compensation terms. The appointment of a COO to lead critical operational functions (legal, compliance, technology, trading services, administration, HR) is material to investors' assessment of the fund's management and governance.
View raw filing on EDGAR →The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be "invaluable as we execute on several key upcoming milestones," indicating material governance strengthening at a pivotal stage for the company.
View raw filing on EDGAR →The disclosure centers on the appointment of Karen Fascenda as Chief Human Resources Officer effective July 6, 2026, succeeding Novelette Murray who retired the same day. While both a departure and appointment occur, the press release and Item 8.01 disclosure emphasize the appointment of the new CHRO with detailed background on her qualifications and experience, making exec_appointment the principal event. The CHRO is a named executive officer role, and the appointment of a successor to a C-suite position is material to investors assessing leadership continuity and human capital strategy.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Choi, Hoe-Yong as a non-standing director of KEPCO, effective July 7, 2026, for a two-year term, replacing former director Mr. Kang, Hoon. This is a clear executive/director appointment event. While non-standing directors may have limited operational authority, director appointments at a major utility company are material to investors' assessment of governance and board composition.
View raw filing on EDGAR →The filing discloses the Board's determination on June 30, 2026 to appoint Gregory R. Allen to fill an open vacancy on the Board of Directors, with his first meeting scheduled for September 29, 2026. While the disclosure includes standard board compensation details and related-party transaction disclosures, the principal action is the appointment of a director to the Board. This is a material governance event affecting the composition of the registrant's board.
View raw filing on EDGAR →Andrew Gelb and Srini Krish were appointed as interim leaders of Fiserv's Financial Solutions business effective July 7, 2026, following the departure of the President.
View raw filing on EDGAR →The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.
View raw filing on EDGAR →The filing discloses the appointment of Evgeny Zaytsev, M.D., Ph.D. as a Class I director effective immediately, with the Board increasing from seven to eight directors. While the section also mentions Fred Middleton's retirement, the principal disclosed action centers on the new director appointment. The appointment includes standard director compensation (annual cash retainer of $40,000 and a 20,000-share option grant vesting over three years), which is material to investors assessing board composition and governance.
View raw filing on EDGAR →The disclosure centers on the appointment of three new directors (Thurman Justice, Lori Goltermann, and Safwan Shabab) to the Board on July 2, 2026, with specified committee assignments and equity grants. While Jeffrey Rhodes' resignation is also mentioned, it is explicitly stated as not resulting from disagreement and is presented as the context for filling vacancies. The principal disclosed action is the appointment of three directors, making exec_appointment the most salient classification.
View raw filing on EDGAR →T-Mobile appointed Chris Sambar as Chief Enterprise Officer, effective no later than October 14, 2026, reporting directly to CEO Srini Gopalan. The appointment represents a material C-suite leadership change to lead the company's enterprise and government businesses.
View raw filing on EDGAR →Manuel Benito Miranda was appointed as a Class II director effective June 30, 2026, filling a vacancy created by an increase in board size from 8 to 9 directors, and was also appointed to the Compensation Committee.
View raw filing on EDGAR →The filing discloses the appointment of Donn Casale as Chief Executive Officer effective immediately and his concurrent appointment to the Board as a Class III director. While the section also mentions Richard Lowenthal's termination without cause, the principal disclosed action centers on Casale's elevation to CEO and board appointment, making this an exec_appointment event. This is material as it represents a change in the company's principal executive officer.
View raw filing on EDGAR →SunPower Inc. appointed Tom Kowalczuk as Chief Financial Officer and Principal Financial Officer effective June 30, 2026. The filing discloses his background, compensation terms ($400,000 base salary, 50% target bonus), and a material equity grant of 1,000,000 RSUs with specified vesting schedules. This is a principal executive appointment material to investors assessing the company's financial leadership.
View raw filing on EDGAR →Four Leaf Acquisition Corp underwent a comprehensive governance restructuring in connection with its strategic repositioning. Three directors (Alvin Wang, Stephen Markscheid, Rahul Mewawalla) and CFO Coco Kou resigned, while three new independent directors (Nanuk Warman, Jay Izso, Mark DiSabato) were appointed to the Board and its committees, and Greg McCraw was appointed as the new CFO.
View raw filing on EDGAR →On June 30, 2026, seven directors—Daniel C. Herz, Jonathan Z. Cohen, Edward E. Cohen, Jeffrey Clifford, Brian L. Frank, Atul Khanna, and Jeffrey Kupfer—were appointed to the board in connection with the IPO, with specific committee assignments established to govern the newly public blank-check company.
View raw filing on EDGAR →Seth Demsey was appointed as co-Chief Executive Officer of Corvex, Inc., effective July 1, 2026, following the Annual Meeting. This appointment represents a material change in the Company's executive leadership.
View raw filing on EDGAR →The press release announces three material executive and board leadership appointments: Tulani Sikwila as Chairman (in addition to CEO), Wendy Luhabe as Independent Non-Executive Director and Lead Independent Director, and Sphe Mchunu as Chief Financial Officer. These are discrete appointments of named executives and directors to key governance and operational roles, with Mchunu's transition from General Counsel to CFO being particularly significant for financial leadership during the company's growth phase and mine restart execution.
View raw filing on EDGAR →Chi Special Acquisition Corp. appointed two new directors, Chung Fu Wing and Shangwei Chen, effective June 2, 2026, to fill board vacancies. The appointments include detailed biographical information and represent a material change to board composition.
View raw filing on EDGAR →Jerome T. Upton, the Company's Executive Vice President and Chief Financial Officer, has been appointed Interim President and Chief Executive Officer effective July 7, 2026. While the filing also discloses that CEO Thomas J. McInerney is taking a temporary leave of absence for health reasons, the principal disclosed action is Upton's appointment to the interim CEO role. This is material as it represents a change in the principal executive officer position, even though it is temporary and the incumbent CEO is on leave rather than departing permanently.
View raw filing on EDGAR →The exhibit is a press release announcing the appointment of Arie Goor as Chief Financial Officer of Core AI Holdings, effective July 1, 2026. The disclosure explicitly states "Core AI Holdings Appoints Arie Goor as Chief Financial Officer" and provides detailed background on his qualifications and prior experience. This is a clear executive appointment of a named officer to a material C-suite position, which would affect a reasonable investor's assessment of the company's leadership and financial management capabilities.
View raw filing on EDGAR →The filing discloses both the retirement of Michael D. Hill as CFO (effective July 27, 2026) and the appointment of David Tamez as interim CFO (effective the same date). While both events occur, the principal action the Board has taken is the appointment of Tamez to fill the CFO role, making exec_appointment the most salient classification. The retirement is contextual background explaining why the appointment was necessary.
View raw filing on EDGAR →Keith R. Wyche was appointed as a member of the Board of Directors of Internet Sciences, Inc., effective July 1, 2026. This is a clear executive appointment disclosed under Item 5.02. The appointment of a new director with substantial experience (including prior board service at NYSE-listed companies) is material to investors' assessment of the company's governance and leadership.
View raw filing on EDGAR →Kathy Elsesser was appointed to Lazard's Board of Directors effective July 7, 2026, and appointed to the Compensation Committee, succeeding Andrew M. Alper as Compensation Committee Chair. Alper retired from the Board after 13 years of service.
View raw filing on EDGAR →The filing discloses the election of Cynthia Paul as a Class I director to the Board of Yext, Inc., effective July 7, 2026. While the disclosure includes compensation details (initial RSU grant of $350,000 and annual equity eligibility), the principal action is the appointment of a new director with substantial experience in investment management and prior board service at multiple public companies. This is a clear exec_appointment event.
View raw filing on EDGAR →Katherine W. Brunelle was named Executive Vice President, Chief Credit Officer effective July 1, 2026, representing a material executive appointment to a senior leadership position. While Ryan A. Smith's transition to Executive Vice President, Commercial Banking is also disclosed, the primary action disclosed is Brunelle's appointment to the chief credit officer role, a key executive position at the bank holding company. The appointment of a senior executive with 20 years of commercial banking and credit experience to lead credit operations is material to investors.
View raw filing on EDGAR →The filing discloses the appointment of John M. Lutz, age 64, to ePlus's Board of Directors on July 6, 2026, increasing the board size from eight to nine directors. Mr. Lutz was also appointed to the Audit Committee and Compensation Committee. The Board determined he is an independent director under Nasdaq rules. This is a clear executive appointment event, material to investors as board composition and committee assignments affect governance and oversight.
View raw filing on EDGAR →Steven Dorwart's appointment as President, Connectivity and Cloud Solutions effective immediately is the principal disclosed action. While Jason Phillips' retirement is also mentioned, the filing centers on the succession and appointment of Dorwart to a key executive role overseeing a major business segment. The press release emphasizes Dorwart's qualifications, experience, and strategic importance to the company's growth trajectory, making the appointment the salient event.
View raw filing on EDGAR →Stephen R. Curley was appointed to the boards of Eagle Bancorp and its subsidiary EagleBank effective July 6, 2026, in connection with his previously announced position as President and Chief Executive Officer. The appointment of a CEO to the board is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.
View raw filing on EDGAR →Kyndryl appointed Ellen Johnson as Chief Financial Officer effective approximately August 6, 2026, and Andrew Bonzani as General Counsel and Secretary effective July 1, 2026. Both appointments include compensatory arrangements reflecting their senior leadership roles.
View raw filing on EDGAR →The exhibit announces the appointment of Rob Slack, PhD, as Chief Scientific Officer of Vicore Pharma, effective immediately. This is a material executive appointment at a clinical-stage biopharmaceutical company, where the Chief Scientific Officer role is critical to research strategy and pipeline development. The disclosure also notes that the prior CSO, Johan Raud, is transitioning to Senior Advisor, which is a secondary departure element but the primary disclosed action is Slack's appointment to the CSO position.
View raw filing on EDGAR →Five individuals—Professor Dr Sir Ralf Speth, Dr. John Llewellyn, Steven G. Osgood, Hideyuki Nakashima, and Steven Robert Armstrong—were appointed to the board of directors effective July 1, 2026 in connection with the IPO, with four designated as independent directors and committee assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →Dylan Marx has been appointed as Chief Executive Officer of Recurrent Energy, the Company's global project development subsidiary, effective immediately. While Ismael Guerrero's departure from the CEO role is also disclosed, the principal action announced is the appointment of Marx to lead a material subsidiary. The filing emphasizes Marx's qualifications and the seamless transition plan, consistent with an executive appointment disclosure.
View raw filing on EDGAR →Hope Lundt was appointed to the Board of Directors of EWSB Bancorp, Inc. and its subsidiary on July 1, 2026, and assigned to the Audit Committee and Governance and Nominating Committee. This is a clear director appointment, the principal disclosed action. The disclosure of standard non-employee director compensation arrangements is incidental to the appointment itself.
View raw filing on EDGAR →The exhibit discloses the appointment of Yoav Har-Even as an independent director of Innoviz Technologies Ltd. effective July 5, 2026, to fill a newly vacant seat. This is a clear executive/governance appointment event. While the filing also mentions James Sheridan's resignation, the principal disclosed action is the appointment of a new director with significant qualifications (former CEO of Rafael Advanced Defense Systems, retired Major General). Board composition changes affecting independent director status are material to investors.
View raw filing on EDGAR →Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, effective August 3, 2026, under a two-year employment agreement. Dr. Nicacio brings 20+ years of pharmaceutical development experience, including pivotal work on TIVDAK®, and expertise in ADCs and HPV-driven oncology directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. The appointment includes material inducement equity awards of $2.1 million.
View raw filing on EDGAR →Effective immediately prior to the spin-off consummation, Midera appointed a complete board of directors (8 members) and executive leadership team, including Mark M. Salman as CEO, Amy A. Campbell as CFO, Mark S. Bowie as COO, and Matthew R. Fuchsen as Chief Strategy Officer.
View raw filing on EDGAR →The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.
View raw filing on EDGAR →The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses multiple executive appointments effective July 1, 2026: Charles Nelson as Chairman and CEO (promoted from President and COO), Ted Warner as President and director (promoted from CFO), and José Rodriguez as Chief Operating Officer (promoted from VP). While the section also includes an executive departure (E. Will Gray II's resignation as director and demotion from CEO to President, Permian), the principal disclosed actions center on the appointments and promotions of three executives to senior leadership roles, with corresponding employment agreement amendments and compensatory arrangements. These leadership changes are material to investors assessing the registrant's governance and strategic direction.
View raw filing on EDGAR →Keel Infrastructure Corp. appointed Ganesh Aiyer as President, effective July 6, 2026, reporting directly to CEO Ben Gagnon. Aiyer brings 25 years of experience from senior roles at Digital Realty Trust, Schneider Electric, and Dell Technologies, and will be responsible for commercial strategy and pipeline expansion. The appointment includes compensatory arrangements comprising a $500,000 base salary, bonus plan eligibility, 100,000 stock options, $1.5M in RSUs, and severance provisions.
View raw filing on EDGAR →On July 1, 2026, the Board appointed Ms. Sha, XIA as a Director of Grande Group Limited to fill the vacancy created by Mr. Ying Wo Sammy, HO's resignation on April 15, 2026. The filing discloses the appointment of a director, her employment agreement with an annual salary of HK$180,000, and her professional background. This is a clear executive appointment event material to investors assessing the company's leadership composition.
View raw filing on EDGAR →The 6-K discloses the Board's resolution on July 3, 2026 to appoint Dr. Michael HE as a director to fill a vacancy created by Mr. Cheung Kam Cheung's prior resignation. The appointment is accompanied by a director's agreement specifying annual cash compensation of HK$120,000. This is a clear executive appointment event under the taxonomy, material to investors as it affects board composition and governance.
View raw filing on EDGAR →The 6-K discloses the appointment of Guangtong Ren as director and Chief Financial Officer, and the appointment of three independent directors (Jun Ma, YiYun Dai, and Han Tang) with committee assignments, all effective July 1, 2026. While the report also mentions concurrent resignations of four directors/officers, the principal disclosed action is the appointment of new leadership, making exec_appointment the primary classification. This is material as it involves changes to the company's senior financial and governance leadership.
View raw filing on EDGAR →Marie Washburn appointed as Senior Vice President and Chief Financial Officer effective July 13, 2026, with compensation terms including $340,000 base salary, 45% performance bonus target, and 130,000 RSUs. Dr. Arjun Desai also appointed to the Board as a Class III director on July 2, 2026.
View raw filing on EDGAR →